Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Every patient with AML needs comprehensive mutation testing at diagnosis and again at progression, yet even effective targeted and venetoclax-based regimens remain noncurative and carry cumulative toxicity.

Venetoclax combinations have become the backbone of AML therapy for older and unfit patients, but drug interactions, dose modifications, and prior hypomethylating agent exposure complicate real-world use.

Early transplant referral, MRD-guided sequencing, and a candid accounting of intensive chemotherapy's costs shape how clinicians move older and high-risk patients toward potential cure.

From intensive induction with targeted add-ons to lower-intensity venetoclax-based combinations, frontline AML therapy now branches by mutation, fitness, and the realistic prospect of cure without transplant.

Performance status, comorbidity indices, and geriatric assessment frame what a patient can tolerate, while insurance, health literacy, and caregiver support often determine what care is actually feasible.

Being able to tolerate intensive chemotherapy is not the same as benefiting from it. The panel weighs psychosocial realities and candid case outcomes in older patients with AML.

Separate risk systems now guide intensive and lower-intensity AML therapy, and objective fitness criteria are replacing the eyeball test in deciding which patients should receive which approach.

Acute myeloid leukemia arises from stem cell mutations and clonal expansion, and while diagnosis is rarely in doubt, genetic testing now shapes every treatment decision that follows.

Experts outline what it takes to build a sustainable CGT program, from governance and SOPs to navigating complex reimbursement landscapes.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective patient management and support.

Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient support and effective communication.

Health care providers discuss the evolving treatment landscape for follicular lymphoma, emphasizing the importance of education and operational readiness for patient care.

Discover effective strategies for monitoring and managing CRS toxicity and ICANS, enhancing patient care and reducing burdens in treatment.

Explore the safety considerations and unique toxicities of bispecific antibodies, including cytokine release syndrome and neurotoxicity management.

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Explore effective operational protocols for managing oncology patients, emphasizing multidisciplinary teamwork and proactive strategies to handle treatment toxicities.

Explore effective operational protocols for managing oncology patients, emphasizing multidisciplinary teamwork and proactive strategies to handle treatment toxicities.

Explore the operational challenges and solutions in administering bispecific therapies for follicular lymphoma, focusing on patient safety and education.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.

A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.

Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting efficacy and safety.

Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes.

Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.

Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications.

Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes.